In addition, we have analyzed HAT1 levels with immunohistochemistry in different types of cancer, and our results show a statistically significant overexpression of HAT1 in lung, brain, breast, prostate, and bladder tumor tissues compared with nontumor tissues; this overexpression is correlated with poor differentiation and more aggressive, invasive, and metastatic tumors with poorer prognoses (unpublished results). This evidence concerns the gene HAT1 and cancer.